Glenmark Pharmaceuticals’ subsidiary — Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc.
According to IQVIA sales data for the 12 month period ending July 2019, the Olux‐E Foam, 0.05% market achieved annual sales of approximately $11.1 million.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
